Vivos Therapeutics, Inc.
General ticker "VVOS" information:
- Sector: Health Care
- Industry: Medical - Devices
- Capitalization: $11.7M (TTM average)
Vivos Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -13.1%.
Estimated limits based on current volatility of 10.1%: low 1.06$, high 1.29$
Factors to consider:
- Total employees count: 154 as of 2022
- Top business risk factors: Economic downturns and volatility, Pandemic risks, Inflationary pressures, Supply chain disruptions, Regulatory and compliance
- Current price 17.7% below estimated low
- Earnings for 12 months up through Q4 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [2.11$, 8.50$]
- 2025-12-31 to 2026-12-31 estimated range: [1.18$, 5.20$]
Financial Metrics affecting the VVOS estimates:
- Positive: with PPE of -1.6 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -53.62 <= 0.07
- Positive: Industry inventory ratio change (median), % of -1.37 <= -0.15
- Negative: Investing cash flow per share per price, % of -2.40 <= -0.65
- Negative: negative Net income
- Positive: 42.60 < Shareholder equity ratio, % of 52.04 <= 64.25
Short-term VVOS quotes
Long-term VVOS plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $16.02MM | $13.80MM | $15.03MM |
| Operating Expenses | $41.05MM | $31.10MM | $26.20MM |
| Operating Income | $-25.03MM | $-17.30MM | $-11.17MM |
| Non-Operating Income | $1.19MM | $3.71MM | $0.04MM |
| R&D Expense | $0.00MM | $0.10MM | $0.00MM |
| Income(Loss) | $-23.84MM | $-13.58MM | $-11.14MM |
| Profit(Loss)* | $-23.84MM | $-13.58MM | $-11.14MM |
| Stockholders Equity | $4.80MM | $0.41MM | $7.95MM |
| Assets | $13.72MM | $10.73MM | $15.28MM |
| Operating Cash Flow | $-19.59MM | $-11.95MM | $-12.69MM |
| Capital expenditure | $0.92MM | $0.80MM | $0.57MM |
| Investing Cash Flow | $-0.92MM | $-0.85MM | $-0.57MM |
| Financing Cash Flow | $0.00MM | $10.92MM | $17.88MM |
| Earnings Per Share** | $-25.90 | $-11.14 | $-2.22 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.